Skye Bioscience, Inc. will present new data on nimacimab, a Phase 2 proof-of-concept study, at ObesityWeek 2025. Results show nimacimab combined with semaglutide resulted in 30% improved weight loss compared to semaglutide alone, with a significant difference in maintaining weight loss and blunting rebound weight gain. Waist circumference also showed improvement with nimacimab plus semaglutide. The presentation will be on November 7, 2025, in Atlanta, Georgia, with details provided by Dr. Louis Aronne. Skye’s CEO and CMO expressed confidence in nimacimab’s potential for obesity treatment, despite initial monotherapy results not showing significant weight loss.

For more information about Skye Bioscience and their research on metabolic health, visit their website at www.skyebioscience.com. Contacts for investor relations and media inquiries are provided for further information. Forward-looking statements were also included in the press release, emphasizing the uncertainty and risks associated with the development of nimacimab and future clinical trials.

Read more at GlobeNewswire: Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek